Evaluation of a Transbronchial Cryoprobe for the Ablation of Pulmonary Nodules: an in Vitro Pilot Study
Overview
Affiliations
Background: Ablation of malignant pulmonary nodules is a novel therapeutic option for patients who cannot undergo surgery. Current transthoracic approaches cause pneumothorax and/or bleeding in a significant number of cases.
Objective: Our purpose with this study was to evaluate cryoablation under in vitro conditions with a commercially available cryosurgery system.
Methods: We used ballistic gelatin to model the thermal conduction of lung tissue. The cryoprobe was inserted in the ballistic gelatin with two thermal sensors, they were placed 0.5 cm and 1.0. cm from the probe, respectively, temperature was measured on both sides. We used single-, double- and triple-freeze protocols to see if we could freeze it to -20 °C.
Results: We achieved - 18.6 ± 3.26 °C on the closer sensor (sensor 1) and - 3.7 ± 4.61 °C on the sensor further away (sensor 2) after 15 min using the single-freeze protocol. Using the dual-freeze protocol, we achieved - 23.2 ± 2,23 °C on sensor 1 and - 16.5 ± 2.82 °C on sensor 2. With the triple-freeze protocol we obtained - 23.5 ± 2.38 °C on sensor 1 and - 19.05 ± 3.22 °C on sensor 2.
Conclusion: With dual-freeze, values above - 20 °C were achieved using nearer sensor data, but a plateau phase occurred as with continuous freezing. Using triple freeze, we reached - 20 °C at a distance of 0.5 cm from the probe, but not at 1 cm; therefore, we did not expand the diameter of the predicted necrosis zone.
Large apical lung cancer treated with CT-guided percutaneous cryoablation.
Suwita B, Skondras E, Dalal P Radiol Case Rep. 2024; 19(4):1528-1532.
PMID: 38312750 PMC: 10837450. DOI: 10.1016/j.radcr.2024.01.021.
Zarogoulidis P, Papadopoulos V, Perdikouri E, Vagionas A, Matthaios D, Ioannidis A J Cancer. 2024; 15(4):880-888.
PMID: 38230209 PMC: 10788723. DOI: 10.7150/jca.90494.
Cryoablation and immunity in non-small cell lung cancer: a new era of cryo-immunotherapy.
Velez A, DeMaio A, Sterman D Front Immunol. 2023; 14:1203539.
PMID: 37671163 PMC: 10475831. DOI: 10.3389/fimmu.2023.1203539.